CION Ameerpet
An autologous (auto) transplant uses your own stem cells to rescue the marrow after high-dose chemotherapy. It's a recognised option for chemo-sensitive relapsed or refractory lymphoma. Here's how the process works and how CION coordinates it end to end.
An autologous stem cell transplant — often shortened to auto transplant — is a treatment that lets doctors give much stronger chemotherapy than the body could normally recover from. The idea is simple: your own blood-forming stem cells are collected and frozen before treatment, so they can be returned afterwards to rebuild your bone marrow. Because the cells are your own, there is no donor and no risk of graft-versus-host disease.
This approach is best understood as a way to deliver a high dose chemo transplant safely. The high-dose chemotherapy is what treats the lymphoma; the stem cells are the "rescue" that allows your blood counts to recover. Auto transplant is most often used when lymphoma comes back after first treatment or does not respond fully, and the disease still responds to further chemotherapy.
This page explains each step, who it suits and what outcomes look like. For the bigger picture of all transplant types, see our overview of stem cell transplant for lymphoma, and to understand the full treatment pathway visit Lymphoma Treatment in Hyderabad.
For chemo-sensitive relapsed Hodgkin lymphoma, both NCCN and ESMO guidelines list high-dose chemotherapy followed by an autologous stem cell transplant as a standard treatment option — the response of the disease to salvage chemotherapy before transplant is one of the strongest predictors of a good outcome. This is why restaging scans are done before a transplant is confirmed. (Source: NCCN Clinical Practice Guidelines and ESMO Clinical Practice Guidelines for Hodgkin and non-Hodgkin lymphoma.)
An autologous transplant is not a first treatment — it is considered in specific situations, and only when the disease still responds to chemotherapy and you are fit enough for the procedure.
When lymphoma returns after first-line treatment but still responds to salvage chemotherapy, an auto transplant offers a chance of durable remission. This is a well-established role in relapsed Hodgkin lymphoma and certain aggressive non-Hodgkin lymphomas.
If lymphoma does not fully clear with initial therapy (refractory), a transplant may be considered after further treatment brings the disease under control. The relapsed or refractory pathway is mapped out step by step with your team.
The single most important condition is that the lymphoma still responds to chemotherapy. Restaging scans after salvage therapy confirm this before a transplant is offered — a key eligibility check under NCCN and ESMO guidance.
Age, organ function and overall fitness are assessed. Where an auto transplant is not suitable, alternatives such as CAR T-cell therapy or an allogeneic (donor) transplant may be discussed.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether your lymphoma has relapsed or you simply want to understand if an auto transplant is right for you, CION's haematology and medical-oncology team can review your case and explain the options clearly.
An autologous transplant is a sequence of carefully timed stages that usually unfolds over several weeks. CION coordinates the whole journey with accredited transplant partners while managing your assessment, chemotherapy pathway and follow-up directly.
Before transplant, chemotherapy (often combined with an anti-CD20 monoclonal antibody for B-cell lymphomas) is given to bring the disease back under control. Restaging scans — usually a PET-CT — confirm the lymphoma is chemo-sensitive, which is essential for the transplant to be worthwhile.
Growth-factor medicines (sometimes with a priming dose of chemotherapy) push stem cells from the marrow into the bloodstream. The cells are then gathered through apheresis — a process much like blood donation — counted, and frozen for later use. This is usually an outpatient step.
You are admitted to the transplant unit for high-dose chemotherapy — the treatment that targets remaining lymphoma cells. These strong doses also suppress the bone marrow heavily, which is precisely why your stem cells were collected first.
Your frozen stem cells are thawed and returned through a drip. Over the next one to three weeks they travel to the marrow and start producing healthy blood cells again — a stage called engraftment. Close monitoring and supportive care manage this recovery period.
Both are stem cell transplants, but they differ in where the cells come from and how they work. Understanding the distinction helps you follow the conversation with your team.
| Feature | Autologous (auto) | Allogeneic (donor) |
|---|---|---|
| Stem cell source | Your own cells | A matched donor |
| Graft-versus-host disease | Not a risk | Possible |
| Immune anti-lymphoma effect | No graft effect | Possible graft-versus-lymphoma effect |
| Typical use in lymphoma | Chemo-sensitive relapsed / refractory disease | Selected situations, often after auto relapse |
| General tolerability | Usually better tolerated | More intensive, higher risks |
This table is a general guide; the right choice depends on your lymphoma subtype, prior treatment and fitness. Read more on our allogeneic (donor) transplant and stem cell transplant overview pages.
How well an autologous transplant works depends most on the lymphoma subtype and how well the disease responded to salvage chemotherapy beforehand. In published series, an auto transplant offers eligible patients with chemo-sensitive relapsed disease a meaningful chance of long-term remission — a role endorsed by both NCCN and ESMO.
To put outlook in context: across all treatment stages, Hodgkin lymphoma carries a favourable overall survival (roughly 80–90% in many published series), while aggressive B-cell non-Hodgkin lymphomas sit around 60–70%. Transplant-specific figures for relapsed disease are lower than these overall numbers and vary widely by situation. These are honest, published, general figures — outcomes vary considerably by individual, and your own team will give you numbers tailored to your subtype, stage and response.
Recovery from the transplant itself takes several weeks, with blood counts, infection risk and supportive care managed closely during engraftment. After discharge, CION delivers your ongoing follow-up and survivorship care directly — including managing chemotherapy side effects and long-term monitoring.
Not everyone is a candidate, and that does not mean options run out. Depending on the subtype, your team may discuss CAR T-cell therapy (also coordinated through accredited partners), bispecific antibodies, immunotherapy and monoclonal antibodies, targeted therapy, involved-site radiation therapy, or a clinical trial. Each is weighed by the tumour board against your specific situation.
Because an autologous transplant uses your own stem cells, there is no risk of graft-versus-host disease — the immune reaction that can complicate a donor (allogeneic) transplant. This is a major reason auto transplant is generally better tolerated and is the preferred transplant choice for chemo-sensitive relapsed lymphoma, per NCCN and ESMO guidance. (Source: NCCN and ESMO Clinical Practice Guidelines for lymphoma.)
Stem cell transplant is coordinated care at CION: the collection, high-dose conditioning and the transplant admission are carried out at accredited partner transplant facilities, while your CION haematology and medical-oncology team guides the whole pathway so you are never handed off to strangers.
Want to know if an autologous transplant fits your situation? Book a free consultation or call 18002028726. You can also explore the full lymphoma hospital and meet the best lymphoma doctors in Hyderabad.
Get a free written second opinion from CION's lymphoma team — especially valuable before committing to a high-dose chemo transplant, so you understand every option first.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.An autologous stem cell transplant — often called an auto transplant — uses your own blood-forming stem cells to rescue the bone marrow after very intensive treatment. The steps are: your stem cells are collected from the bloodstream and frozen, you then receive high-dose chemotherapy to wipe out lymphoma cells, and finally your stored stem cells are returned to rebuild healthy blood counts. Because the cells are your own, there is no donor and no graft-versus-host disease. It is most often used for certain relapsed or high-risk lymphomas. For the wider picture of when a transplant is considered, see our overview of stem cell transplant for lymphoma.
An auto transplant is most commonly considered when lymphoma comes back after first treatment (relapsed) or does not fully respond (refractory), and the disease still responds to further chemotherapy. It is a recognised option in chemo-sensitive relapsed Hodgkin lymphoma and in certain aggressive non-Hodgkin lymphomas, per NCCN and ESMO guidance. The decision depends on the lymphoma subtype, how it responded to salvage therapy, your age and fitness, and results of a full restaging assessment. At CION, this decision is made by a multidisciplinary tumour board. If you are weighing options after a relapse, our page on relapsed Hodgkin lymphoma options explains the pathway.
The key difference is the source of the stem cells. An autologous transplant uses your own stem cells, collected and frozen before high-dose chemotherapy, then returned to you. An allogeneic transplant uses stem cells from a matched donor. Because autologous cells are your own, there is no risk of graft-versus-host disease and the procedure is generally better tolerated — but it does not provide the immune "graft-versus-lymphoma" effect a donor transplant can. Auto transplant is the more common choice for chemo-sensitive relapsed lymphoma; donor transplant is reserved for selected situations. You can compare the two on our allogeneic (donor) transplant page.
Stem cells are usually collected from the bloodstream, not the bone marrow. First, medicines called growth factors (sometimes with a course of chemotherapy) are given to encourage stem cells to move from the marrow into the blood — a step called mobilisation. A few days later, the cells are gathered through a process similar to blood donation, in which blood passes through a machine that separates out the stem cells and returns the rest to you (apheresis). The collected cells are counted, frozen and stored until the transplant. Collection is typically an outpatient procedure carried out at the accredited transplant facility CION coordinates with.
The high-dose chemo transplant approach uses much stronger doses of chemotherapy than standard treatment. The aim is to destroy lymphoma cells that ordinary-dose therapy could leave behind. These high doses also heavily suppress the bone marrow — which is exactly why your stem cells are collected and stored beforehand. After the conditioning chemotherapy is complete, your frozen stem cells are thawed and returned through a drip, where they travel to the marrow and begin producing healthy blood cells again over the following one to three weeks. We describe therapy here by approach rather than by drug name; specific regimens are decided by your transplant team and discussed on our lymphoma treatment page.
Outcomes depend heavily on the lymphoma subtype and how well the disease responded to salvage chemotherapy before transplant — chemo-sensitive disease does considerably better. In published series, autologous transplant offers a meaningful chance of long-term remission for eligible patients with chemo-sensitive relapsed Hodgkin lymphoma and certain aggressive non-Hodgkin lymphomas (per NCCN and ESMO). Broadly, Hodgkin lymphoma carries a favourable overall outlook (roughly 80–90% survival in many series) and aggressive B-cell lymphomas around 60–70%, though transplant-specific figures are lower and vary widely. These are general published figures — outcomes vary by individual, and your team will give you numbers specific to your situation.
CION coordinates autologous stem cell transplant through accredited partner transplant facilities — the collection, high-dose conditioning and the transplant admission itself are carried out there, with CION's haematology and medical-oncology team managing your care pathway before and after. The chemotherapy, immunotherapy and antibody treatment, targeted therapy, radiation, biopsy, bone-marrow examination, restaging and long-term survivorship follow-up are delivered directly at CION. This coordinated model means one team guides you end to end. To begin, book a free consultation or reach our team on 1800 202 8726.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.